Skip to main content

Advertisement

Log in

Superselective α-adrenergic blockers versus transurethral resection of the prostate: a prospective comparison of health-related quality of life outcome after treating patients with benign prostatic hyperplasia

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Purpose

We prospectively evaluated the impact of transurethral resection of the prostate (TURP) versus superselective α-adrenergic blocker treatment on health-related quality of life (HRQOL) in men with clinically diagnosed benign prostatic hyperplasia (BPH).

Patients and methods

A total of 219 patients with lower urinary tract symptoms (LUTS) caused by BPH were recruited in this study. Treatment modalities consisted of standard TURP (n = 104) and tamsulosin medical treatment (n = 115). HRQOL was assessed by SF-36-Item Health Survey 1.0. LUTS were estimated by The International Prostate Symptom Score. Patients’ outcome 4 weeks after treatment was compared to pre-treatment status and to that of the other group. Statistically significant changes in each HRQOL scale from baseline to follow-up period were investigated.

Results

Baseline characteristics were similar in both groups except for the duration of disease before treatment that was longer in TURP group. Both treatments resulted in statistically significant improvements from pre-treatment in all scales of QOL after 4 weeks, with no significant differences observed between the two groups. In medical treatment group, there was a significant association between higher educational level and better QOL in all 8 scales. Our outcomes revealed a significant decrease in the IPSS in both groups but this improvement was more evident in TURP group.

Conclusion

All scales concerning HRQOL were favorably improved 4 weeks after both surgical and medical treatment, and no significant differences were observed between these two treatment modalities for patients with symptomatic BPH. This information may aid patients when deciding which treatment option to take.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chute, C. G., Panser, L. A., Girman, C. J., et al. (1993). The prevalence of prostatism: A population-based survey of urinary symptoms. Journal of Urology, 150, 85–89.

    PubMed  CAS  Google Scholar 

  2. Chow, R. D. (2001). Benign prostatic hyperplasia. Patient evaluation and relief of obstructive symptoms. Geriatrics, 56, 33–38.

    PubMed  CAS  Google Scholar 

  3. Eckhardt, M. D., van Venrooij, G. E., van Melick, H. H., & Boon, T. A. (2001). Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. Journal of Urology, 166, 563–568.

    Article  PubMed  CAS  Google Scholar 

  4. Bruskewitz, R. C. (2003). Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol, 5, 72–80.

    PubMed  Google Scholar 

  5. Kaplan, S. A. (2005). Benign prostatic hyperplasia: Patient perceptions and financial reality regarding the aging American prostate. Journal of Urology, 173, 1852.

    Article  PubMed  Google Scholar 

  6. Arai, Y., Aoki, Y., Okubo, K., et al. (2000). Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: A prospective study. Journal of Urology, 164, 1206–1211.

    Article  PubMed  CAS  Google Scholar 

  7. O’Leary, M. P., Roehrborn, C., Andriole, G., et al. (2003). Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU International, 92, 262–266.

    Article  PubMed  Google Scholar 

  8. Roehrborn, C. G., Van Kerrebroeck, P., & Nordling, J. (2003). Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. BJU International, 92, 257–261.

    Article  PubMed  CAS  Google Scholar 

  9. Narayan, P., Evans, C. P., & Moon, T. (2003). Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Journal of Urology, 170, 498–502.

    Article  PubMed  Google Scholar 

  10. Cambio, A. J., & Evans, C. P. (2007). Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Therapeutics and Clinical Risk Management, 3, 181–196.

    Article  PubMed  CAS  Google Scholar 

  11. Suzuki, H., Yano, M., Awa, Y., et al. (2006). Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: Using international prostate symptom score and rand medical outcomes study 36-item health survey. International Journal of Urology, 13, 1202–1206.

    Article  PubMed  CAS  Google Scholar 

  12. Narayan, P., & Lepor, H. (2001). Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology, 57, 466–470.

    Article  PubMed  CAS  Google Scholar 

  13. Boyd, S. D., & Narayan, P. (1994). Management of benign prostatic hyperplasia. Western Journal of Medicine, 160, 165–166.

    PubMed  CAS  Google Scholar 

  14. Soderdahl, D. W., Knight, R. W., & Hansberry, K. L. (1996). Erectile dysfunction following transurethral resection of the prostate. Journal of Urology, 156, 1354–1356.

    Article  PubMed  CAS  Google Scholar 

  15. Deliveliotis, C., Liakouras, C., Delis, A., et al. (2004). Prostate operations: Long-term effects on sexual and urinary function and quality of life. Comparison with an age-matched control population. Urological Research, 32, 283–289.

    Article  PubMed  CAS  Google Scholar 

  16. Ware, J. E., Jr, & Gandek, B. (1998). Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. Journal of Clinical Epidemiology, 51, 903–912.

    Article  PubMed  Google Scholar 

  17. Montazeri, A., Goshtasebi, A., Vahdaninia, M., & Gandek, B. (2005). The short form health survey (SF-36): Translation and validation study of the Iranian version. Quality of Life Research, 14, 875–882.

    Article  PubMed  Google Scholar 

  18. Bosch, J. L., Hop, W. C., Kirkels, W. J., & Schroder, F. H. (1995). The international prostate symptom score in a community-based sample of men between 55 and 74 years of age: Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. British Journal of Urology, 75, 622–630.

    Article  PubMed  CAS  Google Scholar 

  19. Salinas-Sanchez, A. S., Hernandez-Millan, I., Lorenzo-Romero, J. G., et al. (2001). Quality of life of patients on the waiting list for benign prostatic hyperplasia surgery. Quality of Life Research, 10, 543–553.

    Article  PubMed  CAS  Google Scholar 

  20. O’Sullivan, M., Murphy, C., Deasy, C., et al. (2004). Effects of transurethral resection of prostate on the quality of life of patients with benign prostatic hyperplasia. Journal of the American College of Surgeons, 198, 394–403.

    Article  PubMed  Google Scholar 

  21. Donovan, J. L., Peters, T. J., Neal, D. E., et al. (2000). A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. Journal of Urology, 164, 65–70.

    Article  PubMed  CAS  Google Scholar 

  22. Gacci, M., Bartoletti, R., Figlioli, S., et al. (2003). Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: A prospective study. BJU International, 91, 196–200.

    Article  PubMed  CAS  Google Scholar 

  23. Tascı, A. I., Ilbey, Y. O., Tugcu, V., et al. (2011). Transurethral resection of the prostate with monopolar resectoscope: Single-surgeon experience and long-term results of after 3589 procedures. Urology, 78, 1151–1155.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by the Shiraz University of Medical Sciences. It was extracted from the dissertation NO. 90-5265. We thank Pamela Waltl (AuthorAID in the Eastern Mediterranean) for improving the use of English in the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alireza Aminsharifi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hadi, N., Aminsharifi, A., Sadeghi, A. et al. Superselective α-adrenergic blockers versus transurethral resection of the prostate: a prospective comparison of health-related quality of life outcome after treating patients with benign prostatic hyperplasia. Qual Life Res 22, 1287–1293 (2013). https://doi.org/10.1007/s11136-012-0259-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-012-0259-7

Keywords

Navigation